Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Announces ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer (ASX:NOX)

Noxopharm (ASX: NOX) today reports on the public release at a global oncology conference of 2 sets of clinical data relating to the development of NOX66 (Veyonda®) as a treatment of end-stage ca...read more

Milestone Achieved in the Nyrada Brain Injury Program (ASX:NYR)

Nyrada Inc (ASX: NYR) provides an update on one of its leading programs for treatment of brain injury. Nyrada has shown in a preclinical pharmacokinetic study that its lead candidate compounds ca...read more

Noxopharm announces FDA allows Veyonda Pre-IND Submission for COVID-19 (ASX:NOX)

Noxopharm (ASX:NOX) today announces that on advice from the U.S. Food and Drug Administration (FDA), the Company has lodged a pre-Investigational New Drug (pre-IND) submission for a clinical trial o...read more

Noxopharm - $7.9 Million Fully Underwritten Entitlement Offer Announced (ASX:NOX)

Noxopharm (ASX: NOX) today announces it will undertake a 1 for 2.5 fully underwritten, pro-rata entitlement offer (“Entitlement Offer”) of new fully paid ordinary shares in the Company (...read more

Noxopharm, Abscopal Responses Achieved in Prostate Cancer (ASX:NOX)

Noxopharm (ASX:NOX) today releases details of the radiographic review of its DARRT-1 clinical study and is pleased to report that it shows a major benefit from a combination of Veyonda® and low-...read more

Pipeline Expands With Potential New Brain Cancer Treatment (ASX:NOX)

Highlights: Noxopharm confirms second pipeline drug program Promising new approach to blocking glioblastoma multiforme growth and invasiveness Test compound passes crucial proof-of-principle te...read more

Approval to be sought for COVID-19 Clinical Study in U.S. (ASX:NOX)

Highlights: NOX to seek approval from U.S. FDA for clinical study of Veyonda® in COVID-19patients Objective to block progression of patients with early-stage disease into multi-organfailure ...read more

Noxopharm Investigating Potential COVID-19 Treatment (ASX:NOX)

Highlights: Hudson Institute identifies anti-inflammatory properties of idronoxil as consistent with blocking ‘cytokine storm’ believed responsible for many COVID-19 deaths Pre-clini...read more

Noxopharm Announces Veyonda Awarded First Allowed Patent Application (ASX:NOX)

Noxopharm (NOX:ASX) announces that Australian patent application No. 2016401508 has been allowed by the Australian Patent Office. The patent claims are directed to a suppository formulation includin...read more

Update on Progress in Nyrada Programs (ASX:NYR)

Highlights: Two lead R&D programs progressing as planned and on-budget Brain injury program leads to discovery of a new generation of more potent drug candidates PCSK9 (cholesterol-lowerin...read more

Noxopharm announces LuPIN Prostate Cancer Trial Fully Recruited (ASX:NOX)

Noxopharm (ASX: NOX) advises that the last patient has been enrolled and safely dosed in the ongoing LuPIN Phase I/II clinical trial being conducted by St Vincent’s Hospital Sydney. This compl...read more

Noxopharm announces FDA grants IND approval to Veyonda (ASX:NOX)

Noxopharm (NOX:ASX) announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda® for combination treatment with doxor...read more

Noxopharm Alliance With GenesisCare (ASX:NOX)

Noxopharm (ASX: NOX) is pleased to announce a clinical alliance with oncology services provider GenesisCare to offer a compassionate access program with Noxopharm’s novel lead product candidat...read more

Noxopharm announces pronounced survival benefit in LuPIN interim trial data (ASX:NOX)

Noxopharm (ASX: NOX) is pleased to announce positive interim results from its LuPIN phase I/II clinical trial. The data was presented today during a poster presentation at the ASCO Genitourinary Can...read more

Nyrada, Inc Corporate Presentation (ASX:NYR)

Nyrada listed on the Australian Securities Exchange on 16 January 2020 (ASX:NYR) with a vision to become a high-growth pharmaceutical company, specialising in drug discovery and early stage developm...read more

Viewing: 106 - 120 of 200 Previous | Next